文献速递浆细胞疾病

新药时代不适合移植的老年高危细胞遗传学多发性骨髓瘤患者的一线治疗

Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents.
PubMed 文献 · Leukemia · 2018-03-28

本文综述了针对新诊断多发性骨髓瘤中老年、不适合移植且伴高危细胞遗传学异常(t(4;14)、t(14;16)、del(17p))患者的双药及三药方案临床试验,这些试验按细胞遗传学风险分层报告结局。结论认为,以免疫调节剂(IMiD)为基础联合具有协同作用机制药物(包括新药)的方案,可能在未来研究中帮助克服该脆弱人群的高危细胞遗传学不良预后。

要点

  • t(4;14)、t(14;16)、del(17p)属高危细胞遗传学异常,与更差预后相关。
  • 老年不适合移植的高危细胞遗传学患者生存改善不及其他患者。
  • 迄今尚无方案在该人群显示持续一致生存获益。

核心结论

  • 以IMiD为基础联合具有协同作用机制药物(包括新药)的方案,可能在未来研究中帮助克服该脆弱人群的高危细胞遗传学不良预后。

研究设计与样本

  • 综述,评估了纳入老年、不适合移植且伴高危细胞遗传学异常的新诊断多发性骨髓瘤患者、并按细胞遗传学风险分层报告结局的双药及三药方案临床试验。

主要发现

  • 伴t(4;14)、t(14;16)、del(17p)等高危细胞遗传学异常的患者,以及老年不适合移植患者,生存改善程度不及其他患者。
  • 迄今尚无治疗方案在老年、不适合移植、伴高危细胞遗传学异常的新诊断多发性骨髓瘤患者中显示持续一致的生存获益。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In multiple myeloma, certain cytogenetic abnormalities, such as t(4;14), t(14;16), and del(17p), are considered high risk and are associated with worse prognosis. Patients with these high-risk cytogenetic abnormalities, as well as those who are elderly and transplant ineligible, have not experienced the same degree of improved survival outcomes that other patients have seen with recent advances in the treatment of multiple myeloma. To date, no treatment regimen has demonstrated sustained and consistent survival benefits in elderly, transplant-ineligible patients with high-risk cytogenetic abnormalities and newly diagnosed multiple myeloma. Thus, there is an unmet need to identify effective treatment options for these patients and achieve outcomes parity with standard-risk patients. In this review, we assessed clinical trials of both doublet and triplet regimens for newly diagnosed multiple myeloma that included elderly, transplant-ineligible patients with high-risk cytogenetic abnormalities and that provided outcomes data stratified by cytogenetic risk status. We concluded that regimens containing an IMiD agent as the foundation of therapy, combined with agents that have synergistic mechanisms of action-including novel therapies-may in future investigations help overcome the poor prognosis of high-risk cytogenetic abnormalities in this vulnerable patient population.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Avet-Loiseau H, Facon T. Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents. Leukemia. 2018. PMID: 29720731. doi:10.1038/s41375-018-0098-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。